Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 498-504

  Hutchinson, Peter E ^a   Osborne, Joy E ^a   Lear, John T ^b,e   Smith, Andrew G ^b   Bowers, P William ^c   Morris, Paul N ^a   Jones, Peter W ^d   York, Christopher ^f   Strange, Richard C ^d   Fryer, Anthony A ^d  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c ROYAL CORNWALL HOSPITAL   (United Kingdom)

^d KEELE UNIVERSITY   (United Kingdom)

^e BRISTOL ROYAL INFIRMARY   (United Kingdom)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; VITAMIN D RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; EYE COLOR; FEMALE; GENE FREQUENCY; HAIR COLOR; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; SKIN;

CASE-CONTROL STUDIES; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRONS; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CALCITRIOL; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 17544392528     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Boyle, P., Maisonneuve, P., and Dore, J-F. Epidemiology of malignant melanoma. Br. Med. Bull., 51: 523-547, 1995.
2. Rivers, J. K. Melanoma. Lancet, 347: 803-806, 1996.
3. Mackie, R. M., Smyth, J. F., Soutar, D. S., Watson, A. C. H., McLaren, K. M., McPhie, J. L., Hutcheon, A. W., Smyth, J. F., Calman, K. C., Hunter, J. A. A., MacGillivray, J. B., Rankin, R., and Kemp, I. W. Malignant melanoma in Scotland 1979-1983. Lancet, 2: 859-862, 1985.
4. MacKie, R., Hunter, J. A., Aitchison, T. C., Hole, D., McLaren, K., Rankin, R., Blessing, K., Evans, A. T., Hutcheon, A. W., and Jones, D. H. Cutaneous malignant melanoma, Scotland, 1979-1989. The Scottish Melanoma Group. Lancet, 339: 971-975, 1992.
5. Valverde, P., Healy, E., Sikkink, S., Haldane, F., Thody, A. J., Carothers, A., Jackson, I., and Rees, J. L. The Asp84glu variant of the melanocortin-1 receptor (MC1R) is associated with melanoma. Hum. Mol. Genet., 5: 1663-1666, 1996.
6. Ichii-Jones, F., Lear, J. T., Heagerty, A. H. M., Smith, A. G., Hutchinson, P. E., Osborne, J., Bowers, B., Jones, P. W., Davies, E., Ollier, W. E. R., Thomson, W., Yengi, L., Bath, J., Fryer, A. A., and Strange, R. C. Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. J. Investig. Dermatol., 111: 218-221, 1998.
7. Lafuente, A., Molina, R., Palou, J., Castel, T., Moral, A., and Trias, M. Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multidisciplinary Malignant Melanoma Group. Br. J. Cancer, 72: 324-326, 1995.
8. Wolf, C. R., Smith, C. A. D., Gough, A. C., Moss, J. E., Vallis, K. A., Howard, G., Carey, F. J., Mills, K., McNee, W., Carmichael, J., and Spurr, N. Relationship between the debrisoquine polymorphism and cancer susceptibility. Cancinogenesis (Lond.), 13,: 1035-1038, 1992.
9. Strange, R. C., Ellison, T. Ichii-Jones, F., Bath, J., Hoban, P., Lear, J. T., Smith, A. G., Hutchinson, P. E., Osborne, J., Bowers, B., Jones, P. W., and Fryer, A. A. Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics, 9: 269-276, 1999.
10. INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br. J. Dermatol., 138: 13-21, 1998.
11. Mangelsdorf, D. J., Koeffler, H. P., Donaldson, C. A., Pike, J. W., and Haussler, M. R. 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J. Cell. Biol., 98: 391-398, 1984.
12. Peehl, D. M., Skowronski, R. J., Leung, G. K., Wong, S. T., Stamey, T. A., and Feldman, D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res., 54: 805-810, 1994.
13. Shabahang, M., Buras, R. R., Davoodi, F., Schumaker, L. M., Nauta, R. J., and Evans, S. R. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res., 53: 3712-3718, 1993.
14. Frappart, L., Falette, N., Lefebvre, M. F., Bremond, A., Vauzelle, J. L., and Saez, S. In vitro study of effects of 1,25 dihydroxyvitamin D3 on the morphology of human breast cancer cell line BT20. Differentiation, 40: 63-69, 1989.
15. Janowsky, E. C., Hulka, B. S., and Lester, G. E. Vitamin D levels as a risk for female breast cancer. In: A. W. Norman, R. Bouillon, and M. Thomasset (eds.), Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications, pp. 496-497. Berlin: de Gruyter, 1994.
16. Ingles, S. A., Haile, R., Henderson, B., Kolonel, L., and Gerhard, C. Association of vitamin D receptor genetic polymorphism with breast cancer risk in African-American and Hispanic women. In: A. W. Norman, R. Bouillon, and M. Thamasset (eds.), Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone, pp. 813-814. University of California, Riverside, CA, 1997.
17. Corder, E. H., Guess, H. A., and Hulka, B. S. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomark. Prev., 2: 467-472, 1993.
18. Taylor, J. A., Hirvonen, A., Watson, M., Pittman, G., Mohler, J. L., and Bell, D. A. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res., 56: 4108-4110, 1996.
19. Glass, A. R., Kikendall, J. W., Sobin, L. H., and Bowen, P. E. Serum 25-hydroxyvitamin D concentrations in colonic neoplasia. Horm. Metab. Res., 25: 397-398, 1993.
20. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology, 108: 1083-1086, 1981.
21. 3, α-melanocyte stimulating hormone, and β-estradiol. J. Investig. Dermatol., 91: 593-598, 1988.
22. Cornwell, M. L., Comstock, G. W., Holick, M. R. and Bush, T. L. Prediagnostic serum levels of 1,25-dihydroxyvitamin D and malignant melanoma. Photodermatol. Photoimmunol. Photomed., 9: 109-112, 1992.
23. 3, RXR heterodimerization, transcription (co)factors and polymorphic receptor variants. In: R. Norman, R. Bouillon, and M. Thomasset (eds.), Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone, pp. 210-217. University of California, Riverside, CA, 1997.
24. Haussler, M. R., Whitfield, G. K., Haussler, C. A., Hsieh, J. C., Thompson, P. D., Selznick, S. H., Dominguez, C. E., and Jurutka, P. W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res., 13: 325-349, 1998.
25. Fitzpatrick, T. B. The validity and practicality of sun reaction skin types I through VI. Arch. Dermatol., 124: 869-871, 1988.
26. Gross, C., Eccleshall, T. R., Malloy, P. J., Villa, M. L., Marcus, R., and Feldman, D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J. Bone Miner. Res., 11: 1850-1855, 1996.
27. Spector, T. D., Keen, R. W., Arden, N. K., Morrison, N. A., Major, P. J., Nguyen, T. V., Kelly, P. J., Baker, J. R., Sambrook, P. N., Lanchbury, J. S., and Eisman, J. A. Influence of vitamin D receptor genotype on bone mineral density in postmenopausal women: a twin study in Britain. Br. Med. J., 310: 1357-1360, 1995.
28. Altman, D. G. Practical Statistics for Medical Research, pp. 241-265. London: Chapman and Hall, 1991.
29. Flanagan, L., Ethier, S., and JoEllen, W. Vitamin D-induced apoptosis in estrogen independent breast cancer cells and tumours. In: A. Norman, R. Bouillon, and M. Thomasset (eds.), Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone, pp. 459-460. University of California, Riverside, CA, 1997.
30. 3 metabolites. Cancer Res., 43: 4443-4447, 1983.
31. 3 receptors and actions in human prostate cancer cell lines. Endocrinology, 132: 1952-1960, 1993.
32. Cross, H. M., Pavelka, M., Slavik, J., and Peterlik, M. Growth control of human colon cancer cells by vitamin D and calcium in vitro. J. Natl. Cancer Inst., 84: 1355-1357, 1992.
33. 3: in vivo and in vitro effects on human preleukaemic and leukaemic cells. Cancer Treat. Rep., 69: 1399-1407, 1985.
34. Nagakura, K., Abe, E., Suda, T., Hayakawa, M., Nakamura, H., and Tazaki, H. Inhibitory effect of 1α,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. Kidney Int., 29: 834-840, 1986.
35. Beaty, M. M., Lee, E. Y., and Glauert, H. P. Influence of dietary calcium and vitamin D on colon epithelial cell proliferation and 1,2-dimethylhydrazine induced colon carcinogenesis in rats fed high fat diets. J. Nutr., 123: 144-152, 1993.
36. 3. Cancer Res., 45: 5426-5430, 1985.
37. Ingles, S. A., Ross, R. K., Yu, M. C., Irvine, R. A., La Pera, G., Haile, R. W., and Coetzee, G. A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst., 89: 166-170, 1997.
38. Milde, P., Hauser, U., Simon, T., Mall, G., Ernst, V., Haussler, M., Frosch, P., and Rauterberg, W. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J. Investig. Dermatol., 97: 230-239, 1991.
39. Ingles, S. A., Haile, R. W., Henderson, B. E., Kolonel, L. N., Nakaichi, G., Shi, C. Y., Yu, M. C., Ross, R. K., and Coetzee, G. A. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol. Biomark. Prev., 6: 93-98, 1997.
40. Reintgen, D. S., Cox, C., Slingluff, C. L. J., and Seigler, H. F. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann. Plast. Surg., 28: 45-49, 1992.
41. Miyamoto, K., Kesterson, R. A., Yamamoto, H., Taketani, Y., Nishiwaki, E., Tatsumi, S., Inoue, Y., Morita, K., Takeda, E., and Pike, J. W. Structural organisation of the human vitamin D receptor chromosomal gene and its promoter. Mol. Endocrinol., 11: 1165-1179, 1997.
42. 3 transcriptionally activates the p21 gene leading to the induced differentiation of the myelomonocytic cell line U937. Genes Dev., 10: 142-152, 1996.
43. Liu, M., Lee, M. H., Cohen, M., Bommakanti, M., and Freedman, L. P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev., 10: 142-153, 1996.
44. 3 in HL60 cells. Cancer Res., 56: 264-267, 1996.
45. 3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol. Cell. Endocrinol., 142: 57-65, 1998.
46. Piccinin, S., Doglioni, C., Maestro, R., Vukosavljevic, T., Gasparotto, D., D'Orazi, C., and Boiocchi, M. p16/CDKN2, and CDK4 gene mutations in sporadic melanoma development and progression. Int. J. Cancer, 74: 26-30, 1997.
47. Ohta, M., Berd, D., Shimizu, M., Nagai, H., Cotticelli, M. G., Mastrangelo, M., Shields, J. A., Shields, C. L., Croce, C. M., and Huebner, K. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int. J. Cancer. 65: 762-767, 1996.
48. Platz, A., Hansson, J., Mansson-Brahme, E., Lagerlof, B., Linder, S., Lundqvist, E., Sevigny, P., Inganas, M., and Ringborg, U. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J. Natl. Cancer Inst., 89: 697-702, 1997.
49. Soufir, N., Avril, M. F., Chompret, A., Demenais, F., Bombled, J., Spatz, A., Stoppa-Lyonnet, D., Benard, J., and Bressac-de Paillerets, B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum. Mol. Genet., 7: 209-216, 1998.
50. Tsao, H., Benoit, E., Sober, A. J., Thiele, C., and Haluska, F. G. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res., 58: 109-113, 1998.
51. Garland, F. C., Garland, C. F., Gorham, E. D., and Young, J. F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med., 19: 614-622, 1990.
52. Hanchette, C. L., and Schwartz, G. G. Geographic patterns of prostate cancer mortality. Cancer (Phila.), 70: 2861-2869, 1992.
53. Gorham, E. D., Garland, C. F., and Garland, F. C. Acid haze air pollution and breast and colon cancer mortality in 20 Canadian cities. Can. J. Public Health, 80: 96-100, 1989.
54. Autier, P., Dore, J. F., Schifflers, E., Cesarini, J. P., Bollaerts, A., Koelmel, K. F., Gefeller, O., Liabeuf, A., Lejeune, F., and Lienard, D. Melanoma and use of sunscreens: an EORTC case-control study in Germany, Belgium, and France. The EORTC Melanoma Cooperative Group. Int. J. Cancer, 61: 749-755, 1995.
55. Holly, E. A., Aston, D. A., Cress, R. D., Ahn, D. K., and Kristiansen, J. J. Cutaneous melanoma in women. Am. J. Epidemiol., 141: 923-933, 1995.
56. Pion, I. A., Rigel, D. S., Garfinkel, L., Silverman, M. K., and Kopf, A. W. Occupation and the risk of malignant melanoma. Cancer (Phila.), 75: 637-644, 1995.